南昌那几个医院看精神好南昌第十二医院评价怎么样正规嘛,南昌疑心那家好,南昌哪里能治疗好抑郁,南昌第十二医院治疗精神科收费正规,南昌市第十二医院精神科医院正不正规咋样,南昌精神失常哪里治疗好,南昌市幻觉治疗好的医院

BEIJING, Jan. 9 (Xinhua) -- China's official website for booking train tickets received a daily average of more than 1 billion hits during the first week of January, according to a railway official.Hu Yadong, vice minister of railways, said Sunday that the online ticket sales platform has provided consumers with a convenient way to buy tickets. He also addressed complaints about the fairness of the sales process."Train tickets sold online or by telephone have topped 2 million daily, meaning that around one-third of passengers don't have to wait in line at train stations for several hours to get a ticket," Hu said.However, many Chinese have expressed dissatisfaction with the website, with some people unable to get train tickets home for this year's Spring Festival holiday, a major holiday in China.Several customers posted their complaints on popular microblogging website weibo.com, stating that the booking site often failed due to "too many visits at the same time."The Spring Festival holiday is always a difficult time for China's public transportation authorities. A total of 3.16 billion passenger trips are expected during the holiday, up 9.1 percent from a year earlier, of which 235 million trips will be made via the country's railways, up 6.1 percent year-on-year, said Hu.This year's transport rush in the Spring Festival Season started on Sunday and will end on Feb. 16, according to the Ministry of Railways.

BEIJING, Jan. 8 (Xinhua) -- China's central authorities have highlighted travel safety as the nation on Sunday officially kicked off the world's largest holiday migration, a time in which mass numbers of passengers will be homeward bound for the traditional Chinese Spring Festival.Safe travel has emerged as a hot-button issue facing the government as passenger trips during the 40-day travel peak are expected to hit a record high of over 3 billion.Liu Tienan, vice chief of the National Development and Reform Commission, the country's top economic planner, told the press on Sunday that passenger transport during the period is not looking good as the enormous migration outweighs existing transportation capacities.?A volunteer guides passengers to their train at Chengdu Railway Station in Chengdu, capital of southwest China's Sichuan Province, Jan. 7, 2012. Starting from Jan. 8, 2012, China's transport system will undergo a 40-day travel rush, which is characterized by a hightened passenger flow around the time of the oncoming Chinese New Year.Liu warned of the likelihood of heavy snow and icy rain that could hamper travel while vowing greater efforts to avoid another travel disaster, as was seen in early 2008 when unprecedented heavy snow and freezing rain inundated the south of the country, bringing traffic to a standstill during the peak holiday season.A total of 3.16 billion passenger trips are expected during the next 40 days, up 9.1 percent from a year earlier, of which, 235 million trips will be made via the country's railways, up 6.1 percent year-on-year.Hu Yadong, vice minister of railways, said a daily average of 5.88 million people will make train trips during the period, 340,000 more than the corresponding period in 2011.At the Beijing Railway Station on Sunday, staff members checked passengers' train tickets and ID cards, as an ID-based train ticket purchasing system kicked off nationwide at the start of the new year in an effort to curb ticket scalping.

BEIJING, Jan. 4 (Xinhua) -- The Chinese currency Renminbi, or the yuan, rose 8 basis points to a record high of 6.3001 against the U.S. dollar on Wednesday, according to the China Foreign Exchange Trading System.In China's foreign exchange spot market, the yuan is allowed to rise or fall by 0.5 percent from the central parity rate each trading day.The central parity rate of the yuan against the U.S. dollar is based on a weighted average of prices before the opening of the market each business day.

NEW YORK, Dec. 27 (Xinhua) -- New York City Mayor Michael Bloomberg announced on Tuesday that babies born in the city in 2009 have the record high life expectancy of 80.6 years, an increase of nearly three years since 2000.The rate of 80.6 years is also above the U.S. national rate of 78.2 years. Life expectancy for 40-year-olds in New York increased by 2.5 years (79.5 to 82) from 2000 to 2009, outpacing the national trend of 1.2 year-increase for the same age group in the U.S. as a whole."If you have friends and relatives that you deeply care about, and they live elsewhere, on average if they move to New York City, they will live longer," said Mayor Michael Bloomberg at Lincoln Hospital in Bronx.Bloomberg contributed the life expectancy progress to the city' s health interventions, including its anti-smoking campaign and expanded testing and treatment for the HIV virus.Despite the progress, heart disease, cancer and influenza/ pneumonia continue to rank as the top three leading causes of death in New York City, followed by lung disease and diabetes.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Erwinaze to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy to E. coli derived asparaginase and pegapargase chemotherapy drugs used to treat ALL.Acute lymphoblastic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes, a type of white blood cell. White blood cells help the body fight infection and are formed in the bone marrow.Erwinaze is injected directly into the muscle three times a week and works by breaking down one of the body's protein building blocks (the amino acid, asparagine) that is present in the blood, and is necessary for the growth of all cells. Leukemia cells cannot produce this protein building block. When a patient is treated with Erwinaze the leukemia cells die. Normal human cells are able to make enough asparagine for their own needs through biosynthesis and will not be affected by treatment with Erwinaze."The approval of Erwinaze underscores the FDA's commitment to the approval of drugs for conditions with limited patient populations with unmet medical needs using novel trial endpoints," said Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.Side effects associated with Erwinaze treatment include serious allergic reactions, inflammation of the pancreas, high blood levels of liver enzymes, blood clotting, bleeding, nausea, vomiting and high blood sugar.